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Objective. Increased Wnt signaling in chondrocytes is associated with development of osteoarthritis (OA). However, OA is considered a disease of the entire joint, where the synovium has been attributed an important role in disease pathogenesis and progression. This study was undertaken to determine whether Wnt signaling in synovial tissue could contribute to pathologic development of OA through the production of matrix metalloproteinases (MMPs), and to assess the relationship of synovial expression of Frizzled (FZD) receptors and the Wnt inhibitor FRZB to MMP expression and disease progression in patients with early OA in the Dutch Cohort Hip and Cohort Knee (CHECK) study cohort.
Methods. In mouse knee joints, human WNT8A and mouse Wnt16 were overexpressed using adenoviral vectors, and expression of messenger RNA (mRNA) for MMPs in the synovium was determined by reverse transcription-polymerase chain reaction or Luminex assay. In human synovial tissue from a subgroup of patients with early OA with knee pain enrolled in the CHECK cohort, levels of Wnt family members were assessed for linkage to MMP expression and disease progression. In addition, MMP production in human synovium from patients with end-stage OA was determined after stimulation of Wnt signaling with WNT3A or inhibition with FRZB or DKK1 in the synovium.
Results. Overexpression of WNT8A and Wnt16 in mouse knee joints induced MMP expression in vivo. Expression of MMPs relevant to human OA in the synovium from CHECK study participants significantly correlated with expression of FZD1, FZD10, and FRZB mRNA. Moreover, increased FZD1 mRNA expression and decreased FRZB mRNA expression were observed in CHECK study patients who experienced disease progression compared to those who were nonprogressors. Stimulation of human OA synovium with WNT3A induced the production of various MMPs, whereas inhibition of Wnt signaling with FRZB or DKK1 reduced the production of MMPs.
Conclusion. Wnt signaling in the synovium may potently induce progression of OA via increased production of MMPs.
Osteoarthritis (OA) is one of the most common debilitating diseases worldwide. However, no curative treatment is available. It is now accepted that OA involves all tissues in the joint (1) . Synovial activation, which is present in .50% of OA patients, is involved in cartilage degeneration (2,3).
We previously described strongly increased synovial expression of members of the Wnt signaling pathway in experimental models of OA (4) . Wnt proteins are lipid-modified glycoproteins that bind to Frizzled (FZD) receptors. Binding to both an FZD receptor and the coreceptor low-density lipoprotein receptor-related protein 5 (LRP-5)/LRP-6 activates the b-catenin-dependent canonical Wnt signaling pathway, whereas binding to FZD alone results in noncanonical Wnt signaling (5) .
Various studies have linked aberrant Wnt signaling to the development of OA (6, 7) . A polymorphism in the Wnt inhibitor gene FRZB that decreases its inhibitory activity against Wnt signaling is associated with a higher incidence of OA (8) . Consistent with this observation, absence of Frzb in experimental mouse models increases the level of disease activity during OA (9) . A possible mechanism of action of this increased disease activity might be elevated production of matrix metalloproteinases (MMPs) induced by active Wnt signaling, as has been described in various other diseases (10, 11) .
Whereas most previous studies focused on the relationship between Wnt signaling in the cartilage and the development of OA, in this concise study we investigated whether active Wnt signaling in the synovial tissue results in increased expression of MMPs. Furthermore, we studied the relationship between the expression of members of the Wnt signaling pathway and disease progression in patients with early symptomatic OA from the Dutch Cohort Hip and Cohort Knee (CHECK) study.
MATERIALS AND METHODS
Patients with early OA. Synovial biopsy tissue was obtained arthroscopically from a subgroup of participants with knee pain who were enrolled in the CHECK study, which was initiated to follow up patients with early symptomatic OA. Standardized radiographs were obtained from each patient to determine measurements of joint space width narrowing and osteophyte size, carried out using Knee Images Digital Analysis (12) . At baseline, participants reported having pain and/or stiffness of the knee or hip, were ages 45-65 years, and had not consulted their physician for these symptoms during the 6 months before study entry. Participants with other pathologic conditions that could explain the symptoms were excluded. We determined whether the CHECK study participants showed progression in joint space width narrowing and osteophyte size between the baseline and 5-year follow-up measurements, and participants were accordingly classified as either progressors or nonprogressors. Progression was defined as a decrease in joint space width of $1 mm and an increase in osteophyte size of $4 times. All patients (n 5 5 female patients, mean 6 SD age 60.9 6 4.1 years, 2 progressors and 3 nonprogressors; n 5 4 male patients, mean 6 SD age 55.8 6 2.3 years, 2 progressors and 2 nonprogressors) signed written informed consent to participate in the study. All study protocols involving human tissue were approved by the local ethics committee (CMO ArnhemNijmegen; approval no. 2004-009).
Patients with established OA, and tissue culture. Anonymized synovial tissue specimens were obtained from patients with end-stage OA who were undergoing joint replacement. Punch biopsy specimens were randomly allocated to wells, and 2 punches per well were stimulated in quadruplicate with 300 ng/ml WNT3A (R&D Systems), which is one of the few recombinant canonical Wnt signaling inducers with sufficient bioactivity, or with 10 ng/ml interleukin-1 (IL-1) (R&D Systems). Alternatively, biopsy specimens were incubated with 100 ng/ml FRZB (R&D Systems), 500 ng/ml DKK1 (PeproTech), or IL-1 receptor antagonist (Sobi). All cultures were performed in RPMI 1640 medium, supplemented with 10% fetal calf serum, sodium pyruvate, 100 units/ml penicillin, and 100 mg/ml streptomycin, for 24 hours.
Animals and adenoviral vectors. Adenoviral vectors for human WNT8A and murine Wnt16 were made as previously described (13) . First, 1 3 10 7 plaque-forming units of adenoviral vector was injected into the naive knee joints of 12-week-old male C57BL/6J mice (supplied by Janvier). Mice were housed in filter-topped cages, and water and food were provided ad libitum. The mice were killed 3 days after Figure 1 . Synovial overexpression of Wnt ligands results in increased expression of matrix metalloproteinases (MMPs). WNT8A, a classic example of a Wnt ligand that activates the canonical Wnt signaling pathway, and Wnt16, known to be strongly up-regulated in the joint during experimental osteoarthritis, were overexpressed in mouse synovium by intraarticular injection of 1 3 10 7 plaque-forming units of adenoviral vectors containing human WNT8A or mouse Wnt16; a luciferase adenoviral vector was used as a control. Expression of mRNA for MMPs 2, 3, 9, and 13 was assessed by quantitative real-time reverse transcription-polymerase chain reaction in the synovial tissue (A) and articular cartilage (B) from mice 3 days after overexpression of WNT8A and Wnt16. Bars show the mean 6 SEM relative levels of expression (corrected for the expression of the reference gene GAPDH [2DC t ]) in 6 samples per group. * 5 P , 0.05; ** 5 P , 0.01. adenoviral overexpression. As a control, we used an adenoviral vector for luciferase. Animal studies were approved by the local animal experimentation committee (RU-DEC approval no.
2011-226).
RNA isolation and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). Gene expression was determined using quantitative real-time RT-PCR. Total RNA was isolated using TRIzol reagent (Invitrogen), according to the manufacturer's protocol, after homogenizing the cartilage or synovial tissue with a MagNA Lyser Instrument (Roche). RT-PCR was performed with specific primers and SYBR Green Master Mix, using a StepOnePlus real-time PCR system (Applied Biosystems). Expression levels are presented as DC t values, normalized to the expression values for the reference gene GAPDH.
Protein measurement using Luminex technology. Protein levels in culture supernatants were determined using Luminex multianalyte technology on a Bio-Plex system, in combination with multiplex kits (Millipore). The supernatants in each well were adjusted for the weight of the synovial biopsy tissue, which was determined after cell culture.
Statistical analysis. Statistical analyses were performed using GraphPad Prism software (version 5). For every analysis, data were checked for normality using the D'AgostinoPearson test. Differences between groups were tested using Student's t-test or 1-sample t-test. The number of repeats conducted in each experiment varied (as reported in the Figure  legends) . P values less than 0.05 were considered significant. Correlations were tested with Pearson's correlation coefficients, at a significance level of P , 0.05.
RESULTS
Increased expression of MMPs after overexpression of Wnts in vivo in the synovial tissue. We previously showed that in vivo targeting of the synovium by intraarticular injection of adenoviral vectors for prolonged periods in vivo leads to overexpression of WNT8A, a classic model used to achieve activation of canonical Wnt signaling, and overexpression of WNT16, the levels of which we previously found to be strongly increased in the joint during experimental OA. Adenoviral injection leads to strong overexpression of both Wnt ligands in the synovium, as well as activation of canonical Wnt signaling in the joint and induction of cartilage damage, within 7 days after overexpression (14) . Because the resulting cartilage damage was observed to be associated with formation of neoepitopes linked to cartilage-degrading enzymes, we assessed samples of mouse synovium and articular cartilage to determine whether the overexpression of both Wnt ligands could result in increased expression of MMPs.
The expression levels of messenger RNA (mRNA) for Mmp2, Mmp3, Mmp9, and Mmp13 were significantly increased in the synovium of mice 3 days after overexpression of WNT8A, whereas after overexpression of Wnt16, the levels of mRNA for Mmp3 and Mmp9 were increased ( Figure 1A ). In contrast, no differential expression of Mmp mRNAs was observed in the articular cartilage from mice ( Figure 1B) .
Correlation of expression levels between relevant MMPs and members of the Wnt signaling pathway in human OA. Human synovial biopsy tissue donated by a subgroup of 9 participants with early symptomatic OA in the CHECK study who were followed up over time was assessed to determine whether baseline mRNA levels of relevant MMPs for OA development correlated with the expression of a set of members of the Wnt signaling pathway; these members were selected because they were found to be differentially expressed between disease progressors and nonprogressors in a microarray analysis of the synovial biopsy specimens. We observed that the expression levels of mRNA for MMP1, MMP2, MMP3, and MMP13 correlated inversely with expression of the Wnt inhibitor FRZB, and correlated positively with the expression of the Wnt receptors FZD1 and FZD10, but not FZD8. In addition, FZD1 mRNA expression correlated positively with AXIN2 expression, while FRZB mRNA expression correlated inversely with AXIN2 expression, the latter acting as an indicator of active canonical Wnt signaling. In contrast, MMP9 mRNA levels were not correlated with any of these members of the Wnt signaling pathway (Figure 2A) .
Increased expression of FZD receptors, but decreased expression of the Wnt inhibitor FRZB, in patients with early OA showing disease progression. Subsequently, we investigated the relationship between the expression of members of the Wnt signaling pathway and progression of OA. We observed significantly increased expression of the Wnt receptor FZD1 and significantly decreased expression of the Wnt inhibitor FRZB in patients who were disease progressors, as compared to those who were nonprogressors ( Figure 2B ), which is consistent with the correlation data reported above.
Increased MMP production as a result of Wnt signaling in human synovial tissue from patients with end-stage OA. We next determined whether stimulation of the synovium from patients with end-stage OA with recombinant WNT3A would increase the production of MMPs. For these relatively short-term experiments, we used recombinant WNT3A, as opposed to adenoviral overexpression, in order to better control the dosage and timing. Following WNT3A stimulation of the synovium from patients with end-stage OA, we observed significantly increased concentrations of MMP-1 and MMP-9 proteins, whereas MMP-2 and 1980 VAN DEN BOSCH ET AL MMP-3 proteins showed a trend toward increased production ( Figure 3A) . To test the hypothesis that endogenous Wnt signaling in OA synovium drives the production of MMPs, we incubated human OA synovium with recombinant FRZB (an inhibitor of all Wnt pathways). Following incubation of the synovium with FRZB, we observed significantly decreased production of MMP-2 and MMP-3 ( Figure 3B ). To determine whether this decreased MMP production was the result of inhibition of canonical Wnt signaling, we blocked human OA synovium with recombinant DKK1, which specifically inhibits b-catenin/canonical signaling. This led to decreased protein production of MMP-1 and MMP-3, but not MMP-2 and MMP-9 ( Figure 3C ).
DISCUSSION
The findings from the study reported herein are the first to show that activated Wnt signaling in OA synovial tissue results in increased MMP production, a process that might contribute to cartilage damage. Furthermore, we show that synovial expression of various Wnt receptors and the Wnt inhibitor FRZB is correlated with MMP expression, and that increased FZD1 expression and decreased FRZB expression are associated with disease progression in a cohort of patients with early symptomatic OA.
Until now, research on the relationship between Wnt signaling and OA has mainly focused on the cartilage (6, 7, 9) . In this study, we add to this knowledge by studying synovial Wnt signaling in the context of OA. We previously showed that induction of canonical Wnt signaling by synovial overexpression of WNT8A and Wnt16 resulted in OA-like cartilage lesions in mice, associated with formation of protease neoepitopes (14) . In the present study, we show that overexpression of WNT8A and Wnt16 increased the synovial expression of MMPs that are able to enhance cartilage matrix breakdown. The different extent of MMP regulation by Figure 2 . Correlation between expression of matrix metalloproteinases (MMPs) relevant to human osteoarthritis (OA) and expression of various Wnt signaling members. A, Gene expression analysis by reverse transcription-polymerase chain reaction was performed in freshly isolated synovial tissue from patients with early symptomatic OA enrolled in the Cohort Hip and Cohort Knee (CHECK) study. The relative mRNA expression levels of the Wnt receptors FZD1, FZD8, and FZD10 and the Wnt inhibitor FRZB were assessed for associations with disease progression as measured by MMP1 expression (left), and for correlations with the expression of MMP1, MMP2, MMP3, MMP9, MMP13, and AXIN2 (right). Correlations were determined using the Pearson's correlation coefficient with 95% confidence interval (95% CI). B, Expression of the Wnt receptors FZD1, FZD8, and FZD10 and the Wnt inhibitor FRZB at baseline in synovial tissue from CHECK study participants was compared between patients who showed progression of OA (PR) (n 5 4) and those who were nonprogressors (NP) (n 5 5). Disease progression was defined as an increase in joint space width narrowing of $1 mm and an increase in osteophyte size of $4 times between baseline and the 5-year follow-up measurement. The MMPs in A were chosen because of the relevance for development of OA. The Wnt signaling members in A and B were selected from microarray analysis of the same synovia, in which the expression of these markers was different between progressors and nonprogressors. Circles in A represent individual donors. Bars in B show the mean 6 SEM relative levels of expression (corrected for the expression of the reference gene GAPDH [2DC t ]). * 5 P , 0.05.
WNT8A overexpression as compared to Wnt16 overexpression might be the result of either differences in signaling by the individual Wnts or differences in the efficiency of these adenoviral vectors that might arise during overexpression of the Wnt ligands.
Preferably, we would have used the same Wnt ligand for all experiments. However, we used adenoviral vectors for relatively prolonged in vivo overexpression, since injection of recombinant proteins would result in quick clearance from the joint, whereas recombinant proteins were chosen for the relatively short-term in vitro tissue cultures, allowing tightly controlled dosages and timing. Moreover, tissue specimens are relatively difficult to target with adenoviruses in vitro. We used recombinant WNT3A because this is one of the few recombinant inducers of canonical Wnt signaling that has sufficient bioactivity. Although all of the Wnt ligands used in this study preferentially signal via the b-catenin-dependent canonical Wnt signaling route, the unique characteristics of the individual Wnt ligands and their signaling remain a matter of debate in the field of research on Wnt signaling pathways. Our data show that synovial Wnt signaling increases the production of various MMPs that are relevant for OA development, a finding that is consistent with a study that showed an increase in MMP expression in rheumatoid arthritis fibroblasts upon stimulation with Wnt1 (15) . The discrepancy in regulation of MMP production that was observed after stimulation of Wnt signaling as compared to inhibition of Wnt signaling might derive from the use of synovium from patients with end-stage OA, in whom the expression of various MMPs, such as MMP-3, is likely to be strongly increased. This might also account for the relatively high variation between the separate donors, both in basal MMP expression levels and in the observed effects of the WNT3A, FRZB, or DKK1 proteins.
Whereas Wnt signaling in multiple joint tissues has been studied in the context of OA, this study using synovial tissue from patients in the CHECK study is the first that links synovial expression of FZD1 and FRZB to OA disease progression. This cohort study provides unique opportunities to study disease progression, starting from the initial phases of the disease. Our findings support those of other studies that show continuous b-catenin signaling in fibroblast-like synoviocytes from rheumatoid arthritis patients (15, 16) . Moreover, we show that the expression of various MMPs in the synovium of patients with early symptomatic OA is correlated with expression of members of the Wnt signaling pathway, some of which showed an altered expression in microarray analysis of these synovial samples. Nonetheless, Figure 3 . Increased synovial Wnt signaling induces the production of matrix-degrading matrix metalloproteinases (MMPs) in human osteoarthritis (OA) synovium. A, Synovial biopsy tissue was obtained from patients with end-stage OA undergoing joint replacement. The synovial samples were stimulated with 300 ng/ml recombinant human WNT3A (or interleukin-1b [IL-1b] as a treatment control) for 24 hours, and the fold change in protein levels of MMPs 1, 2, 3, and 9, relative to the untreated control, were measured in the supernatants. B and C, Based on the hypothesis that increased Wnt signaling, and thus increased production of MMPs, is present in OA synovial tissue, the synovial biopsy samples from patients with end-stage OA were incubated with 100 ng/ml recombinant human FRZB (an inhibitor of all Wnt signaling) (B) or 500 ng/ml recombinant human DKK1 (a specific inhibitor of canonical Wnt signaling) (C), and the fold change in levels of MMPs 1, 2, 3, and 9, relative to the untreated control, were assessed 24 hours after the start of the experiment. IL-1 receptor antagonist (IL-1RA) was used as a treatment control. Bars show the mean 6 SEM of 6 samples per experiment. * 5 P , 0.05; ** 5 P , 0.01, versus unstimulated samples. the number of synovium donors was limited, although the nature of the samples, collected at the initial phases of OA, was highly unique. Therefore, further studies with comparable designs would greatly improve insight into the early events that promote OA development. Moreover, these studies should aim to provide more evidence at the protein level, which was not feasible in this study due to the relatively small number of biopsy samples obtained. Moreover, although the results obtained in the various experiments in this study are consistent with each other, we have to mention a possible inflation of the Type I error, since no correction for multiple comparisons has been applied.
In conclusion, in the current study we show for the first time that Wnt signaling, at least partially via the canonical Wnt signaling pathway, in synovial tissue induces the expression of various MMPs that are relevant to the development of OA. Furthermore, we show that increased synovial expression of the FZD1 receptor and decreased expression of the Wnt inhibitor FRZB are associated with disease progression in patients with early symptomatic OA.
